0001415889-24-009885.txt : 20240402
0001415889-24-009885.hdr.sgml : 20240402
20240402204206
ACCESSION NUMBER: 0001415889-24-009885
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240402
FILED AS OF DATE: 20240402
DATE AS OF CHANGE: 20240402
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
CENTRAL INDEX KEY: 0001787092
ORGANIZATION NAME:
STATE OF INCORPORATION: E9
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41989
FILM NUMBER: 24816612
BUSINESS ADDRESS:
STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC
STREET 2: 280 CONGRESS STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: (617) 951-5372
MAIL ADDRESS:
STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC
STREET 2: 280 CONGRESS STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Boundless Bio, Inc.
CENTRAL INDEX KEY: 0001782303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 830751369
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9880 CAMPUS POINT DRIVE
STREET 2: SUITE 120
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: (858) 766-9912
MAIL ADDRESS:
STREET 1: 9880 CAMPUS POINT DRIVE
STREET 2: SUITE 120
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
form4-04032024_120459.xml
X0508
4
2024-04-02
0001782303
Boundless Bio, Inc.
BOLD
0001787092
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
C/O WELLINGTON MANAGEMENT COMPANY LLP
280 CONGRESS STREET
BOSTON
MA
02210
false
false
true
false
0
Common Stock
2024-04-02
4
C
0
189933
A
189933
D
Common Stock
2024-04-02
4
C
0
366300
A
556233
D
Series B Preferred Stock
2024-04-02
4
C
0
3703704
0
D
Common Stock
189933
0
D
Series C Preferred Stock
2024-04-02
4
C
0
7142857
0
D
Common Stock
366300
0
D
On April 2, 2024, the Series B Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date.
On April 2, 2024, the Series C Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series C Preferred Stock had no expiration date.
Wellington Biomedical Innovation Master Investors (Cayman) II L.P. By: Wellington Management Company LLP, as Investment Adviser /s/ Peter McIsaac, Title: Authorized Person
2024-04-02